DUOCAINE (bupivacaine hydrochloride; lidocaine hydrochloride) by R-Pharm US is impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential. Approved for regional anesthesia, analgesia for surgery, dental and 4 more indications. First approved in 2003.
Drug data last refreshed 2h ago · AI intelligence enriched 2w ago
DUOCAINE is a fixed-dose combination injectable local anesthetic containing bupivacaine hydrochloride and lidocaine hydrochloride. It blocks nerve impulses by increasing electrical excitation thresholds and slowing action potential propagation, providing regional anesthesia and analgesia. The product is indicated for regional anesthesia, surgical analgesia, dental procedures, and obstetrical use.
Product is in late-stage maturity with LOE approaching; commercial teams should prepare for generic erosion and focus on brand loyalty and niche positioning.
impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential. In general, the progression of anesthesia is related to the diameter, myelination, and conduction…
Worked on DUOCAINE at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moDUOCAINE offers limited career growth opportunity as a mature, approaching-LOE product with minimal linked job openings. Roles focus primarily on defending market share against generics and managing declining profitability rather than expansion or innovation.